The European Commission has approved, under the EU Merger Regulation, the proposed acquisition of Acelity, Inc. (“Acelity”) by 3M Company (“3M”), both of the US. Acelity and 3M are both active in the supply of advanced wound care products.
In particular, they are active in the supply of moist advanced wound care products, which are medical devices that provide a moist environment that can encourage healing and tissue growth in wounds that have difficulty healing in normal conditions.
In addition, Acelity is a supplier of negative pressure wound therapy devices and kits and 3M is a supplier of film drapes and barrier films, which are used together with negative pressure wound therapy devices and included in certain kits.
The Commission concluded that the proposed transaction would raise no horizontal competition concerns given the companies’ moderate combined market shares in the supply of advanced wound care products (or any plausible sub-segmentations) and the presence of a number of competitors in these markets. Moreover, the Commission did not find any anti-competitive vertical or conglomerate effects resulting from the combination of these businesses.
Full Content: Europa
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – China Edition – Year of the Dragon
Apr 16, 2024 by
CPI
Review Logic and Rules for Concentrations of Undertakings that Do Not Meet the Standard of Notification
Apr 16, 2024 by
CPI
China’s Review of Semiconductor Transactions
Apr 16, 2024 by
CPI
Key Challenges and Tips for Merger Control Filing in China for Listed Companies
Apr 16, 2024 by
CPI
Key Point Review: China SPC Antitrust Judgments in 2023
Apr 16, 2024 by
CPI